
Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Chicago reports first rabies-positive dog in 61 years. What we know. - 2
Washington resident contracts bird flu, first human case in U.S. since February - 3
Yasser Abu Shabab's killing raises questions about Israel's militia strategy in Gaza - 4
New study measures titanium in Apollo rock to uncover Moon’s early chemistry - 5
Some Americans say they'll go without health insurance as ACA rates spike
French high-speed train slams into truck, killing TGV driver
Wegovy maker Novo sharpens consumer focus with board role for Mars CEO
Interstellar comet 3I/ATLAS reveals weird wobbling jets in rare sun-facing tail
Spain's Easter processions draw more tourists amid Iran war
Instructions to Utilize Your Brain science Certification to Work on Corporate Culture
Rediscovering Imagination in Adulthood: Individual Creative Excursions
Journey Lines for Each Explorer: Track down Your Ideal Journey
Could the Star of Bethlehem have actually been a comet?
How to watch 'A Charlie Brown Christmas' for free this weekend













